Table 1.
Characteristics of IFIs (Non–Candida BSI) in the study populations.
| Variable | Candida UTI Without BSI (N = 7) | Candida Meningitis (N = 1) | Malassezia (N = 5) | Aspergillus (N = 2) | Rhodotorula (N = 1) |
|---|---|---|---|---|---|
| Age (days), median (range) | 50 (27-150) | 10 | 90 (60-120) | 86 (22-150) | 50 |
| Gender | Male: 7 | Female | Males: 3; females: 2 | Male: 2 | Female |
| Ethnicity | African American = 3 | African American | African American: 4 | African American: 1 | African American |
| Caucasian = 2 | Caucasian: 1 | Caucasian: 1 | |||
| Others = 2 | |||||
| Site of infection | Urinary tract infection | CNS | Bloodstream infection | Pulmonary | Bloodstream infection |
| Gestational age (weeks) | <28 weeks: 5 | 25 weeks | <28 weeks: 4 | <28 weeks:1 | 29 weeks |
| 28-32 weeks: 1 | 28-32 weeks: 1 | >32 weeks: 1 | |||
| >32 weeks: 1 | |||||
| Birth weight (g) | <1000: 4 | 730 | <1000: 4 | 1000-1500: 1 | 1085 |
| 1000-1500: 1 | 1000-1500: 1 | >1500: 1 | |||
| >1500: 2 | |||||
| Risk factors | Urinary catheter = 7 | CVC, TPN, ABx | TPN: 5 | Immunodeficiency (1), ABx (1) | TPN, ABx |
| Antifungals used | C-AMB = 2 | C-AMB | C-AMB: 2 | L-AMB: 2 | L-AMB |
| L-AMB = 3 | L-AMB: 2 | ||||
| Fluconazole = 2 | Fluconazole: 1 | ||||
| Cure | 5 (71%) | 1 (100%) | 5 (100%) | 1 (50%) | 1 (100%) |
Abbreviations: IFI, invasive fungal infection; BSI, bloodstream infection; UTI, urinary tract infection; CVC, central venous catheter; TPN, total parenteral nutrition; C-AMB, conventional amphotericin B deoxycholate; L-AMB, liposomal amphotericin B.